Objectives. Surfactant protein-D (SP-D), an innate immune defence molecule of the collectin family, is expressed in lungs and additional extrapulmonary epithelia. SP-D has immune modulatory and anti-microbial effects depending on its oligomerization. The ratio of high molecular weight (HMW): low molecular weight (LMW) SP-D in serum is mainly determined by the Met11Thr polymorphism (SNP rs721917). We aimed to study the SP-D serum level and the molecular size distribution in patients with untreated axial spondyloarthritis (axSpA) as compared with control subjects.
Introduction
Axial spondyloarthritis (axSpA) is a core member of the spondyloarthropathies. Synovitis, osteitis and enthesitis in the axial skeleton and peripheral joints are cardinal features shared by these diseases. If left untreated, patients may develop joint deformities and spinal ankylosis. The aetiology of axSpA is unknown. However, both genetic (HLA-B27) [1] and environmental (intestinal bacteria and smoking) factors have been implicated in the development of the disease [2, 3] .
Surfactant protein-D (SP-D) belongs to the collectin family of the innate immune system and acts by regulating the immune response as a soluble pattern recognition receptor [4] . The basic functional unit of SP-D is a homotrimeric structure consisting of four structural domains, a cysteine rich N-terminal crosslinking domain, a collagen domain, a coil-neck domain and a carbohydrate recognition domain. SP-D may further form oligomers and higher order multimers. The distribution of the low molecular weight (LMW) trimeric units of SP-D and high molecular weight (HMW) species in serum depend on a single nucleotide polymorphism (SNP) variation within the SP-D (SFTPD) gene rs721917 [5] . SP-D binds to oligosaccharide or lipid structures on the surface of microorganisms, thereby contributing to microbial elimination through opsonization and phagocytosis. In addition, SP-D exerts anti-inflammatory activities by enhancing the clearance of apoptotic cells and DNA and by inducing T cell proliferation [6, 7] . SP-D in serum comprises both high and low molecular oligomeric variants characterized by different biologic properties including pro-and anti-inflammatory effects [5, 8, 9] . SP-D is mainly expressed and secreted by pulmonary type II alveolar cells and Clara cells but has also been reported on additional mucosal surfaces [10] . Increased SP-D serum levels have been reported in patients with acute and chronic lung diseases [11] . We recently reported that individuals with newly diagnosed RA have subnormal levels of circulating SP-D with a normal molecular size distribution [12] .
The aims of the present investigation were to examine the SP-D serum level and the molecular size distribution in disease modifier untreated patients with axSpA as compared with control subjects.
Methods

Study populations
Patients with X-ray or MRI verified axSpA according to the Assessment of spondyloarthritis (ASAS) criteria [13, 14] , age 1963 years (n = 34), mean disease duration 3.9 (2.25.6) years, were included. Patients from three rheumatology centres in Southern Denmark were recruited from November 2011 through February 2014. Exclusion criteria were age <18 and >75 years, past or present malignancy, congestive cardiac disease (New York Heart Association (NYHA) NYHA IIIIV), pulmonary disease (Dyspnoea at rest), serum concentration of creatinine above the upper normal limit, a serum concentration of ALAT above two times the upper normal limit, hepatitis B or C infection and other chronic inflammatory diseases. Patient characteristics including sex, age, BMI, smoking habits, treatment and HLA-B27 status were recorded. Disease measures included swollen and tender joint counts (68 joints), Spondyloarthritis Research Consortium of Canada enthesitis index, patient pain, global, fatigue and physician disease activity score on a visual analogue scale (0100), BASDAI, BASFI, BASMI and ankylosing spondylitis disease activity score including CRP (ASDAS-CRP). Fifty-seven self reportedly healthy Lebanese individuals (age 1875) served as controls [15, 16] . The study was approved by the local ethics committee (j.nr S-20110086) and all subjects gave written consent in accordance with the Helsinki II Declaration. The Lebanese control group participated in a study approved by the ethics committee of the Lebanese University.
Blood sampling
Non-fasting blood samples from patients with axSpA were collected in plain tubes between 9 a.m. and 4 p.m. They were allowed to clot for 30120 min followed by centrifugation for 12 min at 2200 g. Serum samples were frozen at À80 C degrees until analysis. In the control group, blood samples were collected in EDTA vacutainer or dry tubes for plasma and serum collection, respectively. Plasma and serum were aliquoted and stored at À20 C until analysis. DNA was isolated from peripheral white blood cells from patients and control groups and stored at À80 C [16] .
Laboratory analyses SP-D was measured using a five-layered sandwich ELISA as previously described [11] . All analyses were performed in duplicate. The inter-assay coefficients of variation were 3.5 and 3.8% for low (367 ng/ml) and high (2470 ng/ml) quality controls, respectively, and the intra-assay coefficients of variation were 1.7% for both quality controls.
SP-D gel filtration chromatography
Two hundred microlitre serum samples were applied to an analytical Superose 6 column connected to a fast-performance liquid chromatography system (former Amersham Biosciences, now GE Healthcare, Uppsala, Sweden) using Tris-buffered saline (TBS) (pH 7.4) containing 10 mM EDTA and 0.05% emulphogen as eluent at a flow rate of 24 ml/h. Fractions of 0.2 ml were collected and quantified by the SP-D ELISA. Two structurally different SP-D forms were separated by the chromatographic elution: HMW SP-D (fraction 1018) and LMW SP-D (fraction 2438) [8] . The integrated area under the curves depicting the structural distributions (fraction number vs SP-D protein content) was calculated and used for further statistical analyses [16] .
Genotyping DNA was isolated from EDTA stabilized whole blood. In axSpA patients SNP rs721917 was genotyped using TaqMan Genotyping Assays following the manufacturer's recommendations (Applied Biosystems, Foster City, CA, USA). Genotyping in controls was performed as recently reported [16] . Samples were analysed in an automated sequencer (3130 genetic analyzer, Applied Biosystems 
Results
Demographics
There was a significantly higher proportion of males among axSpA patients (71%) than in the control group (42%) (P < 0.0001) while smokers were more prevalent in controls than in axSpA patients, 51% vs 32% (P = 0.006) ( Table 1) .
Serum SP-D in axSpA does not differ from controls
The SP-D level in patients with axSpA was 1177 ng/ml (869; 1536) vs controls, 910 ng/ml (494; 1682) (P = 0.35).
In the present axSpA cohort there was no difference in SP-D serum level between the rs721917 genotypes, Met11/Met11, 1201 ng/ml (820; 1622), Met11/Thr11 1198 ng/ml (1121; 1444) and Thr11/Thr11 974 ng/ml (869; 1841). Similarly, there was no difference in SP-D serum level between males and females, between smokers and no-smokers, NSAID treated vs untreated patients or between individuals with sacroiliitis on X-ray and those with MRI sacroiliitis only. SP-D did not correlate with composite disease outcome measures or CRP.
Serum LMW SP-D is increased in axSpA
Comparison of the integrated areas under the SP-D elution curves showed that the HMW/LMW SP-D ratio was significantly lower in axSpA patients, 0.38 (0.18; 0.53) than in controls 1.49 (0.37; 3.24) P = 0.0004 (Fig. 1) . This also applied to each Met11Thr polymorphism subgroup, even when adjusting according to gender, age, BMI and smoking (data not shown). There was no correlation between HMW/LMW ratio and CRP, ASDAS, BASDAI, BASFI, BASMI and visual analogue scale scores. Subgroup analysis on the HMW/LMW SP-D ratio according to HLA-B27, tender or swollen joint count, enthesitis or sacroiliitis on Xray vs MRI, was not feasible due to small sample sizes.
Discussion
While SP-D in serum did not differ quantitatively between patients with axSpA and control subjects, the oligomerization pattern of circulating SP-D in disease modifier untreated axSpA patients was significantly distorted towards preponderance of low molecular variants irrespective of the Met11Thr genotype, which is known to affect this distribution. SP-D has not previously been studied in axSpA, while subnormal levels have been reported in early, DMARD naïve RA [12] . However, whereas the molecular size distribution of SP-D in peripheral blood did not differ between RA patients and healthy controls, only LMW variants were detected in SF. This finding may suggest that SP-D is https://academic.oup.com/rheumatology involved in chronic joint inflammation, for example, by deposition in inflamed tissues or complex formation with microbial and cellular waste. This issue was pursued in further detail in the present study in which we investigated the serum distribution of high and low molecular weight SP-D variants in patients with axSpA. In healthy people with the Thr11Thr genotype LMW SP-D predominates, while HMW SP-D predominates in persons with the Met11Met genotype [5] . In the present cohort of DMARD untreated axSpA, the ratio between high and low molecular weight SP-D in serum was significantly skewed towards overweight of LMW variants. Post-translational modifications of SP-D should be considered as a possible background for this altered oligomeric pattern. Thus, it has recently been shown that nitrosylation of cysteine residues in the N-terminals of SP-D (SNO-SP-D) in the course of inflammation may decompose multimeric SP-D into nitrosylated trimeric functional units. Modified trimeric SP-D binds to the calreticulin/CD91 receptor complex and initiates a pro-inflammatory response through phosphorylation of p38 and NF-kB activation [17] . While there was no correlation between the HMW/LMW ratio and clinical or laboratory Disease outcome measures, this does not preclude that the predominantly pro-inflammatory SP-D profile in axSpA patients may contribute to the maintenance of chronic, persistent but clinically silent joint and entheseal inflammation. Thus, the diagnostic delay in axSpA may exceed 5 years due to its frequently non-specific presentation and slow progression, implying that target tissue damage on X-ray or MRI is often present when the diagnosis is established [18] .
Although SP-D is expressed in many different tissues, lungs are supposed to be the main source of SP-D in the circulation [10] . Therefore, a possible link between local pulmonary SP-D metabolism and the axSpA disease pathway should be considered when interpreting the skewed HMW/LMW ratio of SP-D observed in the present study. Pulmonary abnormalities on high-resolution CT have been reported in 4080% of patients with AS including apical fibrosis, emphysema and non-specific interstitial lung disease [19, 20] . Moreover, Fakih et al. [16] recently reported that the multimerization profile of SP-D in serum from patients with inflammatory lung diseases is distorted towards preponderance of lower molecular size variants with proinflammatory activities. It may therefore be hypothesized that the dominant low molecular SP-D oligomers in the circulation of patients with axSpA originate from clinically unrecognized lung inflammation and preferential production of modified trimeric SP-D, which is leaked into the systemic circulation [17] . Considering that the SP-D oligomer profile in serum is normal in RA [12] , the overrepresentation of LMW SP-D in axSpA may be conceived as a distinctive molecular SpA signature that may enhance local or systemic inflammatory responses.
The study has some limitations. First, this is a crosssectional study of DMARD untreated axSpA patients. This design does not allow us to study possible temporal changes in the SP-D molecular size distribution during treatment. The control population was of Lebanese origin. However, the genotype distribution in this population accords well with figures from Denmark [5] . Lung imagings and lung function testings were not available. Finally the site of synthesis of serum SP-D in axSpA remains undetermined. Strengths of this study include that patients were carefully classified and characterized by one rheumatologist (H.L.M.) according to the most recent criteria for axSpA.
Conclusions
In disease-modifier untreated axSpA patients, SP-D in serum did not differ quantitatively from the healthy control level. The molecular size distribution of SP-D was skewed towards predominance of LMW variants, suggesting that SP-D may act as an inflammatory mediator in axSpA. 
